Reach Us +1-218-451-2974


Development Of Novel Neuroprotective Statins To Modify Alzheimer?s Disease | 12531
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Development of novel neuroprotective statins to modify Alzheimer?s disease

International Conference on Psychology, Autism and Alzheimers Disease

Javier S. Burgos

Accepted Abstracts: J Alzheimers Dis Parkinsonism

DOI: 10.4172/2161-0460.S1.004

In recent years a large number of experimental observations have suggested a relationship between cholesterol homeostasis and Alzheimer?s disease (AD). Consequently, statins have been evaluated as neuroprotective drugs for the prevention and treatment of AD, showing benefit in several experimental and epidemiological studies. However, these positive effects are generally not in accordance with placebo-controlled randomized clinical trials (CT). One of the reasons for the failure is the selection of the statin for the CT, especially because the commercially available statins were developed for their plasma-cholesterol lowering effects. Neuron BioPharma is developing a discovery program for the identification of statins especially designed for neuroprotection. To this end, the molecules have been rationally designed, studied by in silico methods, synthesized in small quantities and evaluated for neuroprotective activity by using the exclusive Neuron BioPharma experimental platform that integrates in vitro, cellular and animal models for the study of AD. In this regard, a group of novel neuroprotective statins have been identified and developed, wherein the most advanced derivative (NST0037) will start the First-in-Human phase during this year. The identification and evaluation of a novel statin with a higher neuroprotective profile than the commercial available statins could open a new insight in the AD treatment field, and the use of neuroprotective statins could be considered as a new strategy to modify the disease progression. Moreover, the identification of neuroprotective statins could increase the possibility of success in CT for AD and, consequently, to define a new biomarker scenario to study the AD progression.
Javier S. Burgos holds a Ph.D. in Biology from the Autonomous University of Madrid (Spain). Currently, he is Chief Scientific Officer of Neuron BioPharma, a company focused in the discovery of molecules against neurodegenerative diseases. He has been guest researcher in a number of renowned institutes in the US, South America and Spain. He has published more than 40 scientific articles and contributed to several book chapters, and is inventor of seven patents. He is reviewer of 26 biomedical journals and member of the editorial board of Journal of Alzheimer?s Disease, American Journal of Neurodegenerative Disease, and Journal of Viruses.